Poland· PL-100490988
Lyfnua
A gefapixant product containing gefapixantum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Gefapixant is registered in 13 of 19 countries.
Countries holding a registration under ATC R05DB29 (gefapixant), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Gefapixant · ATC R05DB29
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Gefapixantum
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- R05DB29
- ATC class
- Gefapixant
- Defined daily dose
- 90 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Gefapixant in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLYFNUAMerck Sharp & Dohme B.V., Haarlem
- SpainLYFNUA 45 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Sharp & Dohme B.V.
- FinlandLyfnuaMerck Sharp & Dohme B.V.
- FranceLYFNUA 45 mg, comprimé pelliculéMERCK SHARP & DOHME (PAYS-BAS)
- IrelandLYFNUA 45 mg Film-coated tabletMerck Sharp & Dohme BV,
- IcelandLyfnuaMerck Sharp & Dohme B.V.*
- NetherlandsLyfnua 45 mg filmomhulde tablettenMerck Sharp & Dohme B.V.
- NorwayLyfnuaMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lyfnua
- Liechtenstein · Lyfnua
- Norway · Lyfnua
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df99bf9b-23fd-4a7b-9791-a9105be229c8 GET /v1/drugs/df99bf9b-23fd-4a7b-9791-a9105be229c8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "45 mg",
"packaging": "Rp ¦ EU/1/21/1613/002 ¦ 152407\n56 tabl.\nRp ¦ EU/1/21/1613/003 ¦ 152408\n98 tabl.\nRp ¦ EU/1/21/1613/004 ¦ 152409\n196 tabl.\nRp ¦ EU/1/21/1613/001 ¦ 152410\n28 tabl.",
"substance": "Gefapixanti citras 45 mg",
"common_name": "Gefapixantum",
"pl_product_id": "100490988",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about gefapixant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.